Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes. Issue 1 (January 2023)

• Record Type: Journal Article
• Authors: Pang, Huiwen; Huang, Xiangquan; Xu, Zhi Ping; Chen, Chen; Han, Felicity Y.
• Is Part Of: Drug discovery today. Volume 28:Issue 1(2023)
• Publication Date: 2023-01
• Subjects: Oral insulin -- Poly(lactic co-glycolic acid) (PLGA) -- Biological barriers -- Mucus -- Epithelium -- Gastrointestinal tract (GIT); Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2022.103393
• Languages: English
• ISSNs: 1359-6446

Abstract

Graphical abstract: Highlights: Oral administration of insulin mimics the endogenous insulin secretion. Strategies for PLGA nanoparticles to overcome different barriers for oral insulin delivery are discussed. Challenges and future perspectives of PLGA nanoparticles for oral insulin delivery are also put forward. Abstract: Currently, the only practical way to treat type 1 and advanced insulin-dependent type 2 diabetes mellitus (T1/2DM) is the frequent subcutaneous injection of insulin, which is significantly different physiologically from endogenous insulin secretion from pancreatic islets and can lead to hyperinsulinemia, pain, and infection in patients with poor compliance. Hence, oral insulin delivery has been actively pursued to revolutionize the treatment of insulin-dependent diabetes. In this review, we provide an overview of recent progress in developing poly(lactic co-glycolic acid) (PLGA) nanoparticles (NPs) for oral insulin delivery. Different strategies for insulin-loaded PLGA NPs to achieve normoglycemic effects are discussed. Finally, challenges and future perspectives of PLGA NPs for oral insulin delivery are put forward.